INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune diseases characterised by synovial inflammation and a progressive cell-mediated destruction of joints. 1 Regulatory CD25 positive CD4 T cells (Tregs) expressing Foxp3 control the onset and the development of autoimmune disease. Their depletion in mice results in spontaneous development of several autoimmune diseases like, for example, polyarthritis. 2 Although in autoimmune diseases, Tregs are present in normal frequency and numbers in the periphery and are even enriched at local sites of inflammation like the synovium in RA, their suppressive capacity seems to be diminished. 3 4 On the one hand, the pro-inflammatory milieu characteristic for ongoing autoimmune inflammation, in particular cytokines like tumour necrosis factor (TNF), IL-6, or IL-21, might attenuate Treg suppressive capacity. [5] [6] [7] [8] On the other hand, distinct intrinsic factors, such as genetic factors, may also contribute to a diminished suppressive phenotype of Tregs in RA. For instance, functional polymorphisms in the Foxp3 gene have been reported to be associated with susceptibility to several autoimmune diseases. [9] [10] [11] Moreover, miRNAs have recently been shown to play a critical role in the regulation of the immune function of Tregs as Treg-specific ablation of either one of the two key miRNA-processing enzymes, Dicer or Drosha, results in severe autoimmunity in mice. 12 13 MiRNAs are about 23nt small non-coding RNAs that regulate mRNA expression at the posttranscriptional level by directing mRNA degradation or transcriptional repression.
14 Alterations in miRNA expression levels impact expression of the target genes in a 1.2-fold to 4-fold manner, and represent, therefore, a fine-tuning mechanism regulating protein expression. 15 In RA, altered expression, in particular of two miRNAs, miR-146a and miR-155, has repeatedly been reported to be associated with the disease. Elevated levels of miR-146a and miR-155 were observed in synovial fibroblasts from RA patients as well as in RA synovial tissue. [16] [17] [18] Alterations in the miR-146a expression profile were found in total peripheral mononuclear as well as in CD4 T cells. 19 20 Analysis of the miRNAs in an experimental disease model revealed that treatment of mice with miR-146a in the course of collagen-induced arthritis (CIA) prevented joint destruction, 21 whereas miR-155-deficient mice were completely resistant to the development of CIA. 18 To understand the possible impact of miRNAs on Treg function in RA, we sought to analyse whether expression of miR-146a and miR-155 is altered also in Tregs of RA patients. We observed miR-146a alterations in Tregs and miR-155 alterations in CD4 T cells. Alterations in miR-146a but not miR-155 expression correlated with disease activity. Moreover, it correlated with augmented expression and activation of signal transducer and activator of transcription 1 (STAT1), a direct target of miR-146a, and lead likely to a pro-inflammatory Treg phenotype suggesting an essential role of miR-146a in regulation of suppressor Treg function in RA, and thereby, in RA pathogenesis.
MATERIALS AND METHODS Study population
Peripheral blood was obtained from 61 patients with RA, and 49 age-matched and gender-matched healthy individuals (table 1) . Patients fulfilled the 2010 EULAR/ American College of Rheumatology (ACR), or the ACR 1987 criteria for RA. 22 23 Demographic and clinical parameters, such as age, gender, disease duration, tender joint count on 28 and on 68 joints (TJC28 and TJC68, respectively), swollen joint count on 28 and on 66 joints (SJC28 and SJC66, respectively), rheumatoid factor, anticyclic citrullinated peptide antibodies (Ab), disease activity score in 28 joints (DAS28), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were collected at the time of blood sampling. At the study entree 23/61 of patients were untreated, 17/61 were on steroids either alone or in combination with disease modifying anti-rheumatic drugs (DMARDs) and/or biologics, 35/61 were treated with DMARDs (methotrexate or leflunomide) either alone or in combination with prednisolone and/or biologics, and 19/61 were receiving biologics alone or in combination (TNF inhibitors, tocilizumab, rituximab, or abatacept). All subjects provided written informed consent. The study was approved by the Ethics Committee of the Hospital of the University of Munich.
T cell purification and culture
Tregs and CD25 negative CD4 T cells were purified from human PBMCs by a human CD4-CD25 regulatory T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of Tregs and CD25 negative CD4 T cells was controlled by flow cytometry using monoclonal Abs to CD3, CD4, CD25, and CD127. Typically, ≥95% of isolated cell populations were CD3/CD4 positive. Tregs were ≥90% CD25 positive and ∼80% CD127 negative. CD25 negative CD4 T cells were ≥98% negative for CD25 and ≥98% positive for CD127. The purity and number of the isolated cell populations were comparable between patients and controls (online supplementary figure S1 ). T cells were stimulated with anti-CD3/ CD28-coated beads at a 1:1 cell-to-bead ratio (Dynabeads, Life Technologies, Carlsbad, California, USA) in the presence of 100 U/mL IL-2 (Chiron, Emeryville, California, USA) in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 50 U/mL penicillin G, 50 μg/mL streptomycin, 2 mM L-glutamine (all from Life Technologies) and 10% normal human serum.
RNA extraction and cDNA synthesis
Total RNA was extracted from T cells using the RNeasy Plus Mini kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. 100 to 250 ng RNA were reversely transcribed into cDNA using AffinityScript QPCR cDNA Synthesis Kit (Agilent Technologies, La Jolla, California, USA) according to the manufacturer's instructions.
Real-time PCR analysis
MiR-146a and miR-155 were detected using TaqMan MicroRNA assays (Life Technologies). RNU48 was used as an endogenous cellular short RNA control. MRNA levels were detected using TaqMan Gene Expression Assays (Life Technologies). β-actin was used as an endogenous control. PCRs were performed in duplicates on 7500 Fast Real-Time PCR System (Life Technologies). Relative quantification was performed based on differences in cross-threshold values (ΔCt) between the gene of interest and the endogenous control (ie, Ct (gene of interest)-Ct (endogenous control)). Relative expression of the gene of interest was calculated according to the formula 2 −ΔCt . To compare expression levels in RA patients and healthy controls, threshold value was set to a constant number for each set of experiments.
Luciferase assay
1.2 Mio Tregs were transfected with 5 mg nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) luciferase reporter vector (pGL4.32) and 0.5 mg pRL-TK, a renilla luciferase control reporter vector, (both from Promega) using an Amaxa human T cell Nucleofector kit (Lonza, Cologne, Germany). T cells were distributed into 9 wells of a 96-well plate (100.000 cell/well), and stimulated with either Dynabeads in the presence of 50 U/mL IL-2, or with 10 ng/mL phorbol 12-myristat 13-acetat (PMA) (Sigma-Aldrich) and 1 mM ionomycin (Merck, Darmstadt, Germany), or left non-stimulated; 17 h after transfection, luciferase activity was measured using a Dual-Glo luciferase assay (Promega).
Transfection
Tregs were transfected with 1 mM miRNA mimics or antagomirs using serum-free ACCELL medium (all from Thermo Scientific, Lafayette, Colorado, USA) for 1 h at 37°C. Threefold excess of RPMI-1640 medium supplemented with 1 μM miRNA mimics or antagomirs were added.
STAT1 staining
Freshly isolated or transfected Tregs were stimulated for 24 h with anti-CD3/28-coated beads. Cells were fixed, permeabilised, and then stained with PE-labelled anti-STAT1 (1/Stat1) and Alexa Fluor 647-labelled anti-STAT1 ( pS727) (K51-856) (all from BD Phosflow, San Jose, California, USA).
ELISA
Freshly isolated, or transfected Tregs, were stimulated for 24 h with anti-CD3/28-coated beads. Levels of IFNγ, TNF and IL-17 in cell culture supernatants were assessed using Quantikine ELISA according to the manufacturer's instructions (R&D Systems, San Diego, California, USA).
T cell suppression assays
CD25 negative CD4 T cells were labelled with 10 mM carboxyfluorescein succinimidyl ester (CFSE) (Life Technologies). MiRNA mimics-or antagomir-transfected Tregs were cultured with CFSE-labelled CD25 negative CD4 T cells in a 1:1 ratio in the presence of soluble anti-CD3 and feeder cells for 4 days. Proliferation of CD25 negative CD4 T cells was assessed by flow cytometry based on CFSE dilution. 
Statistical analyses
Statistical analysis was performed using Prism 5.0 Software for Macintosh (GraphPad Software, San Diego, California, USA). Normal distribution was controlled by Kolmogorov-Smirnov. Differences between study cohorts were determined using Student t test. Spearman's rank correlation coefficient was performed to test statistical dependency between two variables; p<0.05 was considered statistically significant.
RESULTS
Diminished expression levels of miR-146a and miR-155 in Tregs from RA Analysis of miR-146a and miR-155 expression in freshly isolated Tregs and CD25 negative CD4 T cells revealed that both miRNAs were expressed at comparable levels in both cell populations. There were no differences in the expression levels between the analysed RA patient cohort and healthy controls ( figure 1A,B) . In response to anti-CD3/CD28 stimulation, expression levels of miR-146a decreased slightly in Tregs, whereas in CD25 negative CD4 T cells they were markedly downregulated (figure 1A). Important was the observation that the expression of miR-146a in Tregs but not in CD25 negative CD4 T cells was significantly lower in RA patients than in healthy controls 1 and 2 days after stimulation. Expression levels of miR-146a in Tregs of RA patients upon T cell receptor (TCR) stimulation accounted for about 70% of the expression levels in healthy individuals (see online supplementary table S1).
By contrast, expression of miR-155 was highly upregulated in response to anti-CD3/CD28 in Tregs and CD25 negative CD4 T cells (figure 1B). Still similar to the expression of miR-146a, expression of miR-155 was significantly lower in RA patients than in controls 1 and 2 days after stimulation. The diminished miR-155 expression in RA seemed, however, to be a rather general characteristic of CD4 T cells and not of Tregs in particular as it was observed in both T cell populations, Tregs and CD25 negative CD4 T cells. Yet, in Tregs of RA patients, expression levels of miR-155 upon T cell receptor (TCR) stimulation accounted for about 50% of the expression levels in healthy individuals (see online supplementary table S1).
Different expression levels of miR-146a but not of miR-155 in RA in patient groups stratified based on disease activity When we stratified the patients based on disease activity into patients with active disease (DAS28 >3.2) and patients with low disease activity (DAS28 ≤3.2), we observed a marked difference in the expression of miR-146a in Tregs (figure 1C). Whereas Tregs from patients with low disease activity expressed high levels of miR-146a comparable with that of healthy controls, Tregs from patients with active disease expressed significantly lower levels of the miRNA. Tregs from patients with active RA expressed around 1.5-fold to 2-fold lower levels of miR-146a as compared to healthy controls or patients with low disease activity (see online supplementary table S2). No such differences between patient groups and healthy controls were observed in CD25 negative CD4 T cells.
Analysis of miR-155 expression revealed that upregulation of the miRNA after TCR stimulation in Tregs was less pronounced in both RA patient groups than in healthy individuals ( figure  1D ). Expression levels of the miRNA were around three-fold lower in RA Tregs than in healthy controls without a difference between the patient groups (see online supplementary table S2). A similar trend was observed in CD25 negative CD4 T cells.
Expression levels of miR-146a correlate with clinical parameters of disease activity
Because of the Treg-characteristic expression pattern of miR-146a in RA, we next carried out a correlation analysis between clinical parameters and expression levels of miR-146a in Tregs (figure 2). Indeed, there was an inverse correlation between DAS28 and the expression levels of miR146a ( figure  2A) . Also, SJC28, SJC66 and TJC28, TJC68 correlated negatively with miR-146a expression (figure 2B,C). By contrast, there were no such apparent correlations between CRP or ESR and miR-146a expression expression ( figure 2D,E) . This confirms our observation that in RA, expression of miR-146a levels in Treg correlates with disease activity.
MiR-146a and miR-155 expression levels in RA do not correlate with expression of their target genes involved in NF-κB signalling Both miRNAs, miR-146a and miR-155, have been reported to be involved in a negative feedback loop regulating the NF-κB signalling pathway. 24 We, therefore, next investigated expression of their target genes within the NF-κB activation pathway in Tregs from RA patients with active disease and with low disease activity ( figure 3 ). MiR-146a has been reported to regulate expression of interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6), 25 whereas miR-155 targets I-κ B kinase epsilon (IKKe). 26 Expression of the IRAK1 mRNA was upregulated in response to anti-CD3/ CD28 stimulation ( figure 3A) . By contrast, expression of TRAF6 and IKKε was rather down-regulated ( figure 3B,C) . Interestingly, expression levels of these three genes were generally higher in RA patients as compared with healthy controls independent of disease activity. NF-κB activity was, however, comparable between patients and controls ( figure  3D ). No correlation was, therefore, observed between the expression levels of miR-146a or miR-155 and the NF-κB signalling pathway (online supplementary figures S2A,B, 3A) .
Correlation of miR-146a expression levels with expression of STAT1 but not of miR-155 with suppressor of cytokine signalling 1 (SOCS1)
When we analysed the expression of two other genes reported to be regulated by miR-146a and miR-155 in particular in Tregs, STAT1 and SOCS1, [27] [28] [29] we observed a striking upregulation of their mRNA expression in response to TCR stimulation from Tregs in patients with active disease but not in healthy controls, and not in the RA patient group with low disease activity ( figure 4A ). The upregulation of STAT1 mRNA in the active group of patients but not in patients with low disease activity correlated well with the downregulation of miR-146 expression in Tregs in patients with active disease but not with low disease activity ( figure 1C, supplementary figure S2C ). Moreover, higher STAT1 protein expression and phosphorylation in response to stimulation in patients with active disease was observed ( figure 4B) .
Expression of SOCS1 ( figure 4A ), a target of miR-155, in Tregs did not correspond with the expression pattern of miR-155 shown in figure 1D (see online supplementry figure  S3C ). Whereas the active RA group demonstrated an increase in SOCS1 expression and a simultaneous down-regulation of miR-155, patients with low disease activity showed diminished expression of both ( figures 1D, 4A) , indicating an additional mechanism controlling SOCS1 expression.
Altered cytokine secretion pattern in Tregs from patients with active RA Alterations in the expression of miR-146a or miR-155, and subsequently of STAT1 and SOCS1, might modify cytokine secretion profiles of CD4 T cells. 27 30 31 We, therefore, next analysed expression of the pro-inflammatory cytokines, IFNγ, TNF, IL-17 and IL-2, in Tregs from RA patients stratified again according to their disease activity ( figure 4C) . In response to anti-CD3/CD28 stimulation, all cytokines were upregulated in Tregs at mRNA level within 24 h and downregulated after 48 h. Strikingly, however, upregulation of cytokine expression was more pronounced in Tregs from RA patients with active disease than in healthy controls or in patients with low disease activity. Patients with low disease activity expressed even diminished levels of the pro-inflammatory cytokines in comparison with healthy controls. The increase of cytokine mRNA after 24 h of stimulation in Tregs of patients with active disease was reflected by cytokine concentrations in cell culture supernatants ( figure 4D ). These data together indicate that in RA, changes in miR-146a or miR-155 expression might indeed lead to alterations in the Treg phenotype.
Cytokine secretion pattern, but not the suppressive capacity of Tregs correlates with miR-146 and miR-155 expression
To verify this hypothesis we next analysed cytokine expression in Tregs treated with either mimics or antagomirs of miR-146a and miR-155 ( figure 5A ). Indeed, treatment with mimics of miR-146a Figure 1 MiR-146a and miR-155 expression levels in Tregs and CD25 negative CD4 T cells. Tregs and CD25 negative CD4 T cells were isolated and stimulated with anti-CD3/CD28 beads for a total of 2 days. MiRNA expression was assessed in freshly isolated (d0) and in stimulated cells at 24 h (d1) and 48 h (d2) by real-time PCR using TaqMan gene expression assays. MiRNA expression in relation to expression levels of RNU48 is demonstrated. Expression levels of miR-146a (A) and of miR-155 (B) in 24 healthy controls (HC) and 19 patients with rheumatoid arthritis (RA). (C, D) Expression of miR-146a (C) and miR-155 (D) in 24 HC and in RA patient stratified according to disease activity: patients with active disease-RA DAS28 >3.2 (n=8) and patients with low disease activity-RA DAS28 ≤3.2 (n=11). Data are shown as box plots demonstrating minimum, maximum, median and 25th and 75th percentiles. *p<0.05, **p<0.01, ***p<0.001 by Student t test. reduced cytokine secretion, whereas mimics of miR-155 increased the cytokine production. Neutralisation of the miRNA effects through antagomirs led to opposite results. Interestingly, however, once both miRNAs were mimicked or neutralised simultaneously, the cytokine secretion profile was rather similar to that observed during manipulation of miR-146a (figure 5A). The intervention with miR-146a led also to significant alterations in STAT1 expression and phosphorylation (figure 5B). Whereas mimicking of miR-146a diminished STAT1 expression and phosphorylation, neutralisation of the miRNA increased both. Remarkably, despite the pronounced effect on cytokine expression profile, intervention with the expression of these two miRNAs did not affect the in vitro suppressive capacity of Tregs ( figure 5C ).
DISCUSSION
Based on the apparent deregulation of miR-146a and miR-155 expression in RA and, moreover, their critical involvement in the onset of arthritis in animal models, we have investigated in the current study expression of miR-146a and miR-155 in Tregs, and have analysed their impact on Treg function in patients with RA.
We observed a diminished expression of both miRNAs, miR-146a and miR-155, in Tregs of patients indicating some disease-dependent abnormalities in the regulation of their expression. MiR-146a and miR-155 are widely expressed and are involved in the differentiation and activation of both, the innate and the adaptive immune systems. 32 In particular, miR-146a has been initially reported to be upregulated in macrophages in response to TLR-mediated NF-κB signalling. 25 33 MiR-146a seems to be an important player in the NF-κB signalling pathway in innate immunity as it downregulates the NF-κB signalling transducers, IRAK1 and TRAF6 and, thereby, calms NF-κB signals.
Observations from miR-146a-deficient mice suggest that also in CD4 and CD8 T cells, miR-146a might be upregulated in response to TCR-mediated NF-κB signalling and, in turn, might downregulate NF-κB activity through repressing IRAK1 and TRAF6. 34 Interestingly, however, we did not observe an upregulation of miR-146a in response to TCR stimulation, either in Tregs or in CD25 negative CD4 T cells, despite NF-κB-activation that occurred in response to our stimulatory conditions (figures 1A, 3D). The human origin of the cells in our study allows us, therefore, to suggest different signalling pathways downstream of TCR signalling in CD4 T cells in humans than in mice that result in miR-146a expression. Moreover, evidence suggests that Figure 2 Correlation between clinical parameters and the expression levels of miR-146a in Tregs in rheumatoid arthritis (RA). Tregs were isolated and stimulated with anti-CD3/CD28 beads for a total of 2 days. MiRNA expression was assessed in freshly isolated (d0) and in stimulated cells at 24 h (d1) and 48 h (d2) by real-time PCR using TaqMan gene expression assays. MiRNA expression in relation to the expression levels of RNU48 is demonstrated. Disease activity on 28 Joints (DAS28) (A), swollen joint count on 28 joints (SJC28) and SJC66 (B), tender joint count on 28 joints (TJC28) and TJC68 (C), C-reactive protein (CRP) (D) and erythrocyte sedimentation rate (ESR) (E) were plotted against the miR-146a expression levels at d0, d1 and d2. Correlations were determined by Spearman's rank correlation coefficient.
changes in the T cell phenotype in response to miR-146a deletion might occur not necessarily only as a result of NF-κB signalling but also because of augmented expression of other target genes of miR-146a, like for example, STAT1. 27 In our study, we indeed observed a marked correlation between miR-146a and STAT1 expression, but not between miR-146a and IRAK1 or TRAF6 expression (online supplementary figure  S2 ). IRAK1 and TRAF6 mRNAs were upregulated in patients with active and non-active disease, while miR-146a expression was downregulated only in patients with active RA (figures 1C, 3A). Putative binding sites for miR-146a can be predicted in the 3 0 UTR of murine and human IRAK1 and TRAF6 mRNAs. Moreover, miR-146a-mediated regulation of the expression of human IRAK1 and TRAF6 has been shown in an in vitro setting. 25 Yet, it might well be that in vivo expression of these two critical molecules of the NF-κB signalling pathway at least in humans is subject to a complex and not only to a simplified miR-146a-mediated switch-on/off regulatory mechanism. In this regard, Pauley et al 19 reported normal IRAK1 and TRAF6 expression in a bulk of mononuclear cells of RA patients despite the observed 2.6-fold increase in miR-146a expression.
Similar to miR-146a, miR-155 has been reported to be induced by NF-κB signalling. 24 The result of NF-κB-induced miRNA expression, however, appears to be rather contrary between miR-146a and miR-155. Whereas miR-146a rather calms the pro-inflammatory immune response, miR-155 enhances inflammation. Deletion of miR-146a leads to a sizable proportion of IFNγ-producing CD4 T cells and hyperresponsiveness of macrophages to LPS. 27 35 MiR-146a-deficient mice spontaneously develop autoimmune disorders. 35 MiR-155, in turn, diminishes the magnitude of the immune response in macrophages and dendritic cells. 32 Mice deficient for miR-155 are biased towards Th2 differentiation and are resistant to Th17-driven autoimmune inflammation. 18 30 31 36 Interestingly, we did observe these opposite effects of both miRNAs. Tregs from active RA patients expressed on the one hand increased levels of STAT1, a target gene of miR-146a, promoting a pro-inflammatory phenotype of the cells, and on the other hand elevated levels of SOCS1, a target of miR-155, which negatively regulates inflammation (figure 4). Additionally, treatment with mimics and antagomirs led also to opposite effects on cytokine expression ( figure 5A) . Nevertheless, the resulting phenotype of Basic and translational research the Tregs was rather pro-inflammatory in patients with active disease, as expression of IL-17, TNF and IFNγ was elevated ( figure 4C,D) . Thus, it appears as if the pro-inflammatory effect of reduced miR-146a expression prevails over the counteracting impact of reduced miR-155 expression, leading to pro-inflammatory alterations of the phenotype of Tregs in RA. This became obvious when we interfered with the biological activity of both miRNAs simultaneously (figure 5A). The observed diminution of miR-155 expression may, therefore, reflect an attempt of Tregs to counteract the unwanted pro-inflammatory STAT1-mediated effects by upregulation of its natural antagonist, SOCS1.
The preponderance of miR-146 over miR-155 with regard to their impact on Treg function in RA was reflected by the correlation of miR-146 but not of miR-155 with clinical parameters of disease activity. Interesting in this regard was the fact that miR-146a correlated with indicators of local joint inflammation, for example, TJC and SJC, but not with parameters suggestive of systemic inflammation, for example, CRP and ESR (figure 2). This finding suggests that miR-146a-mediated alterations in the Treg phenotype were of particular importance in synovial inflammation although it should be noted that no difference in miR-146a expression levels were detected between Tregs from the peripheral circulation and matched synovial samples (online supplementary figure S4) . In this regard, it is interesting that diminution of miR-146a (as of miR-155) expression became only evident in response to activation indicating that the effect of these alterations strikes primarily during an ongoing immune response like, for example, local inflammation in the joint. By contrast, systemic inflammation appears to be less dependent on Treg function. In accordance with our finding, Tang et al 21 have observed that in CIA, systemic administration of an analogue to miR-146a prevented joint destruction but failed to completely ameliorate inflammation. Likewise, in lupus, decreased levels of miR-146a in leukocytes were also associated with kidney inflammation, a prominent organ manifestation in lupus, but not with systemic inflammatory activity. 37 Our data on miR-146a expression appear to be in contrast to a publication by Li et al 20 reporting increased expression of miR-146a in CD4 T cells from patients with RA. The patient cohort analysed in that paper is, however, different to ours. The patients from the previous study had long-lasting disease (∼5 years), very active RA (DAS28 6.35±1.45), and yet were DMARD naive. By contrast, the untreated patients included in our study had symptoms of the disease for less than 1 year (8.2 ±11.2 months) and a DAS28 of 5.02±1.13. It might be speculated that long-lasting inflammation without any treatment in the patients analysed by Li et al might have led to secondary events influencing the miRNA expression profile that are not related to primary Treg alterations in RA. The fact that Li et al observed extremely elevated ESR (67.94±21.19 mm/h) may support this hypothesis. On the other hand, we cannot completely exclude that the glucocorticoide or the antirheumatic therapy might at least in part have influenced results of our study. The preliminary observation that anti-TNF-treatment was associated with a change in miR-146a levels may support this notion (online supplementary figure S4) . In any case, the strong correlation between miR-146a expression and disease activity independent of the therapy observed by us (figure 2) argues for a direct dependence of miRNA expression in Tregs and disease activity.
The pro-inflammatory phenotype of Tregs characterised by enhanced cytokine production in RA was also observed by others. 38 Inflammatory conditions might force Tregs to become unstable and adopt a phenotype that is more characteristic of effector CD4 T cells during the evolution of an autoimmune disease. 39 40 Altered expression of miR-146a in RA Tregs might thus be the molecular correlate of such phenotypic alterations of Tregs. As reduced expression of miR-146a was particularly prominent in patients with early, treatment-naive RA patients and in patients with active disease, but not in patients with wellcontrolled or long-standing disease, our observation might argue for a role of diminished Treg function during disease onset and in disease flairs. Moreover, they might argue for a Treg control of autoimmune inflammation at rather local, organspecific sites and not at the level of systemic inflammation. Our findings indicate that a deregulated miRNA expression in Tregs might lead to harmful alterations in their phenotype and provide, therefore, novel indications for the involvement of miR-146a and miR-155 in RA pathogenesis.
